Category: 3. Business

Siemens to support Airbus in decarbonizing major industrial locations | Press | Company
[{“name”:”Home”,”site_name”:”Press | Company | Siemens”,”description”:””,”url_str”:”\/global\/”,”level”:0,”image”:””,”base_root”:”https:\/\/press.siemens.com”,”base_nid”:”5″,”base_nodepath”:”\/node\/5″,”base_path”:”\/global\/”,”base_secure_url”:”https:\/\/press.siemens.com\/global”,”children”:[{“name”:”Products & Solutions”,”tid”:0,”url_str”:”https:\/\/www.siemens.com\/global\/en\/products.html”,”alias”:”https:\/\/www.siemens.com\/global\/en\/products.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“name”:”Industries”,”tid”:1,”url_str”:”https:\/\/xcelerator.siemens.com\/global\/en\/industries.html”,”alias”:”https:\/\/xcelerator.siemens.com\/global\/en\/industries.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“name”:”Company”,”tid”:2,”url_str”:”https:\/\/www.siemens.com\/global\/en\/company.html”,”alias”:”https:\/\/www.siemens.com\/global\/en\/company.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]}]}]

[{“nid”:0,”name”:”Products & Solutions”,”tid”:0,”url_str”:”https:\/\/www.siemens.com\/global\/en\/products.html”,”alias”:”https:\/\/www.siemens.com\/global\/en\/products.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Industries”,”tid”:1,”url_str”:”https:\/\/xcelerator.siemens.com\/global\/en\/industries.html”,”alias”:”https:\/\/xcelerator.siemens.com\/global\/en\/industries.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Company”,”tid”:2,”url_str”:”https:\/\/www.siemens.com\/global\/en\/company.html”,”alias”:”https:\/\/www.siemens.com\/global\/en\/company.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]}]
Press Release13 October 2025Siemens AGMunich

Siemens and Capgemini working toward decarbonization of four Airbus industrial locations in the U.S. and the UK

By 2030, the program aims to cut energy consumption by 20% and CO₂ emissions by 85%

Digital twins of the energy system to help develop scalable solutions

Siemens and Airbus have joined forces
to decarbonize four major industrial locations for the aerospace company in the
U.S. and the UK. The framework agreement aims to significantly reduce the
company’s environmental
footprint through targeted cuts to its CO₂ emissions and overall energy use. Siemens is
being supported by Capgemini, which is supporting among other things, with initial
consulting activities, project management and planning. The first phase of the collaboration began in
the summer of 2025 with the development of concrete decarbonization plans. The
target: by 2030, Siemens technologies will have enabled the reduction of energy
consumption at the four Airbus locations by 20% and CO₂ emissions by 85%, to support
Airbus in reaching the overall target of 80 Kt CO2e abated annually from 2030.

Siemens and Capgemini working toward decarbonization of four Airbus industrial locations in the U.S. and the UK

By 2030, the program aims to cut energy consumption by 20% and CO₂ emissions by 85%

Digital twins of the energy system to help develop scalable solutions

Siemens and Airbus have joined forces
to decarbonize four major industrial locations for the aerospace company in the
U.S. and the UK. The framework agreement aims to significantly reduce the
company’s environmental
footprint through targeted cuts to its CO₂ emissions and overall energy use. Siemens is
being supported by Capgemini, which is supporting among other things, with initial
consulting activities, project management and planning. The first phase of the collaboration began in
the summer of 2025 with the development of concrete decarbonization plans. The
target: by 2030, Siemens technologies will have enabled the reduction of energy
consumption at the four Airbus locations by 20% and CO₂ emissions by 85%, to support
Airbus in reaching the overall target of 80 Kt CO2e abated annually from 2030.

The decarbonization roadmaps for the individual
Airbus locations include scalable solutions to reduce energy demand and CO₂
emissions. For this purpose, digital twins of the energy system will be used to
simulate energy consumption in order to identify optimal packages of measures
for the locations. These measures include on-site power supply from renewable
energy sources, heat pumps for heat generation, improvements in energy efficiency, intelligent metering systems
and smart energy management systems for monitoring, controlling and optimizing
consumption at the locations. The
expansion of the infrastructure is scheduled to begin in 2026. Siemens will
also operate and maintain the new systems to ensure long-term efficiency and
resilience.

Siemens and Airbus have been collaborating
successfully for more than half a century. Key initiatives to date include
factory automation, industrial software, safety and security, and building
automation.

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Read more
HQCOPR202510067249EN
Continue Reading
October 13, 2025
Investcorp Announces Final Close of Golden Horizon Cooperation Fund at $750 Million

13 Oct 2025

Investcorp, a leading global alternative investment firm, is pleased to announce the successful final close of its Golden Horizon Cooperation Fund (the “Platform”), launched in collaboration with China Investment Corporation (CIC), one of the world’s largest sovereign wealth funds. The Platform secured commitments from a diverse group of global institutional investors and LPs, including Jada Fund of Funds (a subsidiary of PIF), Saudi Venture Capital, Silk Road Fund, and Bank of China, among others spanning the GCC, Asia, and China.

The Platform is focused on investing in high-growth, profitable companies across Consumer, Healthcare, Transportation & Logistics, and Business Services sectors in the GCC and China. Its objective is to foster cross-border expansion and value creation, with Investcorp and our Chinese partners providing strategic support to help portfolio companies scale and deepen commercial ties between the two regions.

To date, the Platform has completed three investments in the GCC: NourNet, a leading ICT services provider in Saudi Arabia, serving over 1,500 clients across more than 20 industries; Trukker, MENA’s largest on-demand digital trucking aggregator, operating across the Middle East and Europe with over 70,000 trucks and 1,200 B2B enterprise clients; and Salla, Saudi Arabia’s leading SaaS e-commerce enablement platform, which has facilitated over $9 billion in e-commerce GMV since 2020 and currently supports more than 100,000 active merchants.

This milestone underscores Investcorp’s commitment to building strategic investment bridges between the GCC and China, seeking to unlock long-term value for investors and portfolio companies alike.

Continue Reading

October 13, 2025
Siemens partners with Airbus to decarbonize major industrial sites in the U.S. and U.K. | Press | Company
[{“name”:”Home”,”site_name”:”Press | Company | Siemens”,”description”:””,”url_str”:”/global/”,”level”:0,”image”:””,”base_root”:”https://press.siemens.com”,”base_nid”:”5″,”base_nodepath”:”/node/5″,”base_path”:”/global/”,”base_secure_url”:”https://press.siemens.com/global”,”children”:[{“name”:”Products & Solutions”,”tid”:0,”url_str”:”https://www.siemens.com/global/en/products.html”,”alias”:”https://www.siemens.com/global/en/products.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“name”:”Industries”,”tid”:1,”url_str”:”https://xcelerator.siemens.com/global/en/industries.html”,”alias”:”https://xcelerator.siemens.com/global/en/industries.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“name”:”Company”,”tid”:2,”url_str”:”https://www.siemens.com/global/en/company.html”,”alias”:”https://www.siemens.com/global/en/company.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]}]}]

[{“nid”:0,”name”:”Products & Solutions”,”tid”:0,”url_str”:”https://www.siemens.com/global/en/products.html”,”alias”:”https://www.siemens.com/global/en/products.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Industries”,”tid”:1,”url_str”:”https://xcelerator.siemens.com/global/en/industries.html”,”alias”:”https://xcelerator.siemens.com/global/en/industries.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]},{“nid”:0,”name”:”Company”,”tid”:2,”url_str”:”https://www.siemens.com/global/en/company.html”,”alias”:”https://www.siemens.com/global/en/company.html”,”level”:1,”image”:{“fid”:false,”furl”:””},”options”:{“menu_icon”:{“fid”:false},”external”:true},”depth”:1,”parent”:false,”children”:[]}]
Press Release13 October 2025Siemens AGZug,
Switzerland

Siemens to work toward the decarbonization of four Airbus industrial sites in the U.S. and U.K. as part of Airbus’ program to reduce its operational environmental footprint

Program aims to cut energy consumption by 20 percent and Scope 1 and 2 stationary emissions by 85 percent by 2030

Replicable solutions include renewable energy integration, smart energy management, and low-carbon heat systems, delivered in collaboration with Capgemini

Siemens and Airbus
are strengthening their long-standing partnership with a new strategic contract
to work toward the decarbonization of Airbus’ major industrial sites in the
U.S. and U.K. The initiative is a key milestone in Airbus’ program to minimize
the company’s operational environmental footprint through targeted reductions
in CO₂ emissions and energy consumption, among other efforts.

Siemens to work toward the decarbonization of four Airbus industrial sites in the U.S. and U.K. as part of Airbus’ program to reduce its operational environmental footprint

Program aims to cut energy consumption by 20 percent and Scope 1 and 2 stationary emissions by 85 percent by 2030

Replicable solutions include renewable energy integration, smart energy management, and low-carbon heat systems, delivered in collaboration with Capgemini

Siemens and Airbus
are strengthening their long-standing partnership with a new strategic contract
to work toward the decarbonization of Airbus’ major industrial sites in the
U.S. and U.K. The initiative is a key milestone in Airbus’ program to minimize
the company’s operational environmental footprint through targeted reductions
in CO₂ emissions and energy consumption, among other efforts.

Left to right: Sabrina Herrmann – Head of Buildings Germany,
Siemens Smart Infrastructure; Benoit Shultz – Chief Procurement Officer,
Airbus; Herbert Klipp – Corporate Account Manager, Siemens; Carl Ennis – CEO
Siemens UK & Ireland; Jan Schwarz – Vice President Real Estate &
Facility Management Procurement, Airbus; Florent Massou dit Labaquère, EVP
Operations Commercial Aircraft, Airbus; Carsten Liesener – Global Head Sales
& Operations, Siemens Smart Infrastructure; Charles Huguet – Senior Vice
President General Procurement, Airbus

As part of the
framework agreement, Siemens will deploy its scalable and proven
decarbonization solutions, tailored to the selected sites, to support Airbus in
reaching the target of 80 kt CO₂e abated annually from 2030.

The project will be led by Siemens’ Buildings
business and supported by Capgemini, combining the companies’ vast expertise in
sustainability and digitalization to ensure the success and timely delivery of
the project.

Decarbonization at
scale: Scalable solutions for measurable impact

Siemens will evaluate the sites and create
and implement an overall decarbonization masterplan for the awarded sites,
resulting in scalable solutions to reduce energy demand and carbon emissions.
To accelerate the selection of the measures, Energy System Twins will simulate
and help determine the best decarbonization roadmaps for the sites. The key
elements that will enable this include decarbonization of heat production via
heat pumps, energy efficiency upgrades, smart metering systems, on-site smart integration
of renewable energy, and smart energy management systems to monitor, control,
and optimize usage across the sites. These measures are designed to help Airbus
achieve its targets of reducing energy consumption by 20 percent and Scope 1
and 2 greenhouse gas emissions by 85 percent through 2030, compared to 2015
levels.

Capgemini has been appointed by Siemens for
the program to complete first phase consulting activities, governance
definition, and support for project management and planning. Capgemini also brings
its expertise in the digitalization and automation of the
energy monitoring and measurement systems.

“Our collaboration with Airbus is built on
years of mutual trust and shared ambition. It highlights Siemens’ capability to
deliver smart and scalable technologies and services to reduce the carbon
footprint of Airbus. At Siemens, we’re committed to making the energy
transition not only sustainable, but also achievable and scalable, so that
Airbus and other industrial leaders can confront climate challenges while
boosting operational resilience and long-term competitiveness,” said Susanne
Seitz, CEO of Buildings at Siemens Smart Infrastructure.

“We’re proud to be taking this important step
toward making our operations more energy-efficient and future-ready.
Collaborating with trusted partners is key in building a more resilient
industrial footprint. The site-specific expertise from our Airbus colleagues in
the U.K. and the U.S. combined with Siemens’ technical know-how will keep us on
the path toward meeting our energy use and emission reduction targets,” said
Florent Massou dit Labaquere, EVP Operations of Airbus Commercial Aircraft.

Roadmap to 2030

The initial phase began in summer 2025 with the
development of decarbonization roadmaps for each site. Engineering studies will
guide the implementation, with infrastructure rollout starting in 2026. Siemens
can also operate and maintain the new infrastructure, ensuring long-term
efficiency and resilience.

Siemens and Airbus have been working together
for more than half a century. Key initiatives have included factory automation,
industrial software, safety and security, building automation technology, and
beyond. This new agreement builds on successful collaboration to support
Airbus’ sustainability ambitions and achieve its targets for minimizing its
operational environmental footprint.

Siemens Smart Infrastructure (SI) is shaping the market for intelligent, adaptive infrastructure for today and the future. It addresses the pressing challenges of urbanization and climate change by connecting energy systems, buildings, and industries. SI provides customers with a comprehensive end-to-end portfolio from a single source – with products, systems, solutions, and services from the point of power generation all the way to consumption. With an increasingly digitalized ecosystem, it helps customers thrive and communities progress while contributing toward protecting the planet. To protect this journey, we foster holistic cybersecurity to ensure secure and reliable operations. Siemens Smart Infrastructure has its global headquarters in Zug, Switzerland. As of September 30, 2024, the business had around 78,500 employees worldwide.

Read more

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
In fiscal 2024, which ended on September 30, 2024, the Siemens Group generated revenue of €75.9 billion and net income of €9.0 billion. As of September 30, 2024, the company employed around 312,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at www.siemens.com.

Read more
HQSIPR202510027246EN
Continue Reading
October 13, 2025
EWEC signs PPA with Engie and Masdar for 1.5 GW Khazna solar project (UAE) – Enerdata
1. EWEC signs PPA with Engie and Masdar for 1.5 GW Khazna solar project (UAE) Enerdata
2. Abu Dhabi awards contract for a mega solar project The Times of India
3. Masdar Unveils World’s First Gigascale 24/7 Solar and Battery Storage Project to Deliver Continuous Clean Power SolarQuarter
4. Engie, Masdar win 1.5 GW solar project in UAE pv magazine International
5. French Engie and Emirati Masdar win contract for Abu Dhabi for mega solar project The Arab Weekly
Continue Reading
October 13, 2025
Transcriptomic profiles of endocrine-resistant breast cancer | BMC Cancer
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

PubMed

Google Scholar
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32: 1216–1235.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–82.

CAS
PubMed

Google Scholar
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

CAS
PubMed

Google Scholar
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

PubMed
PubMed Central

Google Scholar
Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

Google Scholar
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26-35.

PubMed

Google Scholar
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

CAS
PubMed

Google Scholar
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

CAS
PubMed
PubMed Central

Google Scholar
Confederation of Regional Cancer Centres in Sweden. National Clinical Cancer Care Guidelines Breast Cancer. 2024. https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/brost/vardprogram/nationellt-vardprogram-brostcancer.pdf (Accessed 24 Oct 2024).
Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300.

CAS
PubMed

Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341–1352.
Herzog SK, Fuqua SAW. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022;126:174–86.

CAS
PubMed

Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382–392.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388:2058–70.

CAS
PubMed
PubMed Central

Google Scholar
Bidard F-C, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246–56.

CAS
PubMed
PubMed Central

Google Scholar
Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO guideline clinical insights. JCO Oncol Pract 2024; : OP2400547.
AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25:S18–27.

CAS
PubMed
PubMed Central

Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377:1836–46.

PubMed
PubMed Central

Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717.
Miranda F, Prazeres H, Mendes F, Martins D, Schmitt F. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers. Mol Biol Rep. 2022;49:717–33.

CAS
PubMed

Google Scholar
Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer–An overview and update. Mol Cell Endocrinol. 2015;418(Pt 3):220–34.

CAS
PubMed
PubMed Central

Google Scholar
Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322.

CAS
PubMed

Google Scholar
Dustin D, Gu G, Fuqua SAW. ESR1 mutations in breast cancer. Cancer. 2019;125:3714–28.

PubMed

Google Scholar
Saatci O, Huynh-Dam K-T, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691–710.

CAS
PubMed

Google Scholar
Haque MM, Desai KV. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front Endocrinol. 2019;10:573.

Google Scholar
Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 2020;37:496–513.

CAS
PubMed
PubMed Central

Google Scholar
Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration. J Natl Cancer Inst. 2018;110:803–11.

PubMed
PubMed Central

Google Scholar
Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011;119:92–101.

PubMed

Google Scholar
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34:645–59.

CAS
PubMed

Google Scholar
Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28:105–13.

CAS
PubMed

Google Scholar
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–71.

CAS
PubMed

Google Scholar
BEA core facility. Bioinformatics and Expression Analysis. http://www.bea.ki.se/ (accessed 5 Mar2023).
Thermo Fisher Scientific Inc. Transcriptome Analysis Console (TAC) v4.0.3 User Guide. Affymetrix Inc., 2022https://www.thermofisher.com/content/dam/LifeTech/Documents/PDFs/TAC_v4.0.3_User_Guide.pdf (accessed 24 Oct2024).
Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.

CAS
PubMed

Google Scholar
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

CAS
PubMed
PubMed Central

Google Scholar
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739–1740.
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25.

CAS
PubMed
PubMed Central

Google Scholar
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27. https://doi.org/10.1093/nar/28.1.27.

Article
CAS
PubMed
PubMed Central

Google Scholar
Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672–8. https://doi.org/10.1093/nar/gkad1025.
The Broad Institute. GSEA User Guide. GSEA. 2004–2024. http://www.gsea-msigdb.org/gsea/doc/GSEAUserGuideFrame.html?_Interpreting_GSEA_Results (Accessed 24 Oct 2024).
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.

CAS
PubMed
PubMed Central

Google Scholar
Rueda OM, Sammut S-J, Seoane JA, Chin S-F, Caswell-Jin JL, Callari M, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399–404.

CAS
PubMed
PubMed Central

Google Scholar
Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

PubMed
PubMed Central

Google Scholar
Bhuva D, Smyth G, Garnham A. msigdb: An ExperimentHub Package for the Molecular Signatures Database (MSigDB). R package version 1.14.0. 2024. https://davislaboratory.github.io/msigdb.
Zhao X, Rødland EA, Tibshirani R, Plevritis S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 2015;17:29.

CAS
PubMed
PubMed Central

Google Scholar
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

PubMed
PubMed Central

Google Scholar
R Foundation for Statistical Computing, Vienna, Austria. R: A language and environment for statistical computing. https://www.R-project.org/.
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, et al. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse. Clin Cancer Res. 2017;23:3035–44.

CAS
PubMed

Google Scholar
Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, et al. Independent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor–positive HER2-positive breast cancer treated with neoadjuvant anti–HER2-based therapy. Clin Cancer Res. 2021;27:3116–25.

CAS
PubMed
PubMed Central

Google Scholar
Microsoft Corporation. Microsoft® Excel® for Microsoft 365 MSO. Available from: https://office.microsoft.com/excel.
Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol 2021; 39: 2720–2731.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700–1712.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736–1747.
Yu NY, Iftimi A, Yau C, Tobin NP, van ’t Veer L, Hoadley KA et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal A or luminal B breast cancer. JAMA Oncol 2019; 5: 1304–1309.
Ignatov A, Eggemann H, Burger E, Ignatov T. Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 2018;144:1347–55.

PubMed
PubMed Central

Google Scholar
Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20:1298–305.

CAS
PubMed

Google Scholar
Clusan L, Ferrière F, Flouriot G, Pakdel F. A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int J Mol Sci 2023; 24. https://doi.org/10.3390/ijms24076834.
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905–31.

CAS
PubMed

Google Scholar
Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135–70.

CAS
PubMed
PubMed Central

Google Scholar
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. Breast. 2015;24(Suppl 2):S60–6.

PubMed

Google Scholar
Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126:545–62.

CAS
PubMed

Google Scholar
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40.

PubMed

Google Scholar
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.

CAS
PubMed

Google Scholar
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018;36:1556–63.

CAS
PubMed
PubMed Central

Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

CAS
PubMed

Google Scholar
Wang X, Sun Z, Zimmermann MT, Bugrim A, Kocher J-P. Predict drug sensitivity of cancer cells with pathway activity inference. BMC Med Genomics. 2019;12:15.

PubMed
PubMed Central

Google Scholar
Belachew EB, Sewasew DT. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Front Endocrinol. 2021;12: 599586.

Google Scholar
Harvell DME, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, et al. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008;112:475–88.

CAS
PubMed

Google Scholar
Liang X, Briaux A, Becette V, Benoist C, Boulai A, Chemlali W, et al. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). J Hematol Oncol. 2018;11:124.

CAS
PubMed
PubMed Central

Google Scholar
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Matsuyama R et al. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci 2020; 21. https://doi.org/10.3390/ijms21082921.
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid OM, Nagahashi M et al. The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer. Cells 2020; 9. https://doi.org/10.3390/cells9071643.
Shen W-J, Zhang Y. RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway. Discov Oncol. 2024;15:25.

CAS
PubMed
PubMed Central

Google Scholar
Althobiti M, El-Sharawy KA, Joseph C, Aleskandarany M, Toss MS, Green AR, et al. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Res Treat. 2021;189:621–30.

CAS
PubMed
PubMed Central

Google Scholar
Oshi M, Tokumaru Y, Angarita FA, Yan L, Matsuyama R, Endo I et al. Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. Cancers 2020; 12. https://doi.org/10.3390/cancers12123557.
Takeshita T, Tokumaru Y, Oshi M, Wu R, Patel A, Tian W, et al. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. Front Oncol. 2022;12: 865024.

CAS
PubMed
PubMed Central

Google Scholar
Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19:2057–70.

CAS
PubMed
PubMed Central

Google Scholar
Schroth W, Mürdter TE, Schwab M. Unraveling the impact of drug metabolism on tamoxifen response in breast cancer. Cancer Epidemiol Biomarkers Prev. 2025;34(2):221–3.

CAS
PubMed

Google Scholar
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162–80.

CAS
PubMed
PubMed Central

Google Scholar
Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA. Cytoscape and EnrichmentMap Nat Protoc. 2019;14(2):482–517.

CAS
PubMed

Google Scholar
Bull C, Byrne RM, Fisher NC, Corry SM, Amirkhah R, Edwards J, et al. Dual gene set enrichment analysis (dualGSEA); an R function that enables more robust biological discovery and pre-clinical model alignment from transcriptomics data. Sci Rep 2024 4;14(1):30202.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14(1):4221.

CAS
PubMed
PubMed Central

Google Scholar
Wimmer I, Tröscher AR, Brunner F, Rubino SJ, Bien CG, Weiner HL, et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. Sci Rep. 2018;8:6351.

PubMed
PubMed Central

Google Scholar
Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018;172(1–2):373-386.e10.

CAS
PubMed

Google Scholar

Category: 3. Business

Siemens to support Airbus in decarbonizing major industrial locations | Press | Company

Continue Reading

Investcorp Announces Final Close of Golden Horizon Cooperation Fund at $750 Million

Continue Reading

Siemens partners with Airbus to decarbonize major industrial sites in the U.S. and U.K. | Press | Company

Continue Reading

EWEC signs PPA with Engie and Masdar for 1.5 GW Khazna solar project (UAE) – Enerdata

Continue Reading

Transcriptomic profiles of endocrine-resistant breast cancer | BMC Cancer

Continue Reading

Banks that don’t meet recapitalisation target will downgrade their licences – Yemi Cardoso

Continue Reading

4th ASEAN+3 Economic Cooperation and Financial Stability Forum (AMRO Forum) – ASEAN+3 Macroeconomic Research Office

Continue Reading

Écija: AI, external capital and expansion in Latin America

Continue Reading

BA stalls over paying out £220 flight compensation | Money

Continue Reading

Fairfax Sells Eurolife Life Insurance Business Stake to Eurobank for $945 Million

Continue Reading